Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

694
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
694
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

730
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
730

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonmetallic Si Doping Constructs Cu<sub>2</sub>O/Co-O-Si Tandem Sites for Neutral Nitrate Reduction Electrocatalysis Toward Ammonia Recovery and Energy-Integrated Applications.

Angewandte Chemie (International ed. in English)·2026
Same author

Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study.

Frontiers in cardiovascular medicine·2026
Same author

Hollow MnO<sub>2</sub> nanosystem for glioblastoma sono-immunotherapy based on blood-brain barrier crossing and oxygen supply strategy.

Journal of colloid and interface science·2026
Same author

Contrast-enhanced ultrasound enhancement-pattern classification for procedure selection and perioperative outcomes in cesarean scar pregnancy.

Frontiers in surgery·2026
Same author

Microemulsion flooding based on surfactant system: Recent advances and current challenges in enhanced oil recovery.

Advances in colloid and interface science·2026
Same author

Accelerated Reaction Exploration across Scales: A Hybrid Operando and Modeling Study of Oxidation Kinetics in Monolayer Tungsten Disulfide.

Journal of the American Chemical Society·2026

Related Experiment Video

Updated: Dec 22, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K

Biomarkers for Allogeneic HCT Outcomes.

Djamilatou Adom1,2,3, Courtney Rowan1,2,3, Titilayo Adeniyan1,2,3

  • 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States.

Frontiers in Immunology
|May 7, 2020
PubMed
Summary

Hematopoietic cell transplantation (HCT) offers cures but faces challenges like graft-versus-host disease (GVHD) and relapse. Biomarkers discovered through omics technologies are improving diagnosis, prognosis, and treatment for GVHD and graft-versus-tumor effects.

Keywords:
biomarkersgraft-versus-host diseasegraft-versus-tumorhematopoietic cell transplantationproteomics

More Related Videos

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

16.2K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K

Related Experiment Videos

Last Updated: Dec 22, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

16.2K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.8K

Area of Science:

  • Biomedical Science
  • Immunology
  • Oncology

Background:

  • Allogeneic hematopoietic cell transplantation (HCT) is a curative option for hematological disorders.
  • Graft-versus-host disease (GVHD) and disease relapse limit HCT success.
  • The graft-versus-tumor (GVT) effect is crucial for preventing relapse.

Purpose of the Study:

  • To review the role of biomarkers in HCT.
  • To summarize omics technologies and their application in biomarker discovery.
  • To discuss current and emerging biomarkers for GVHD and GVT.

Main Methods:

  • Review of recent literature on "omics" technologies and systems biology.
  • Analysis of diagnostic, prognostic, and predictive biomarkers for GVHD and GVT.
  • Inclusion of machine learning approaches for identifying GVHD predictors.

Main Results:

  • Omics technologies have enabled discovery and validation of blood biomarkers.
  • Biomarkers aid in diagnosing, prognosing, and predicting response to therapy for GVHD and GVT.
  • Machine learning can identify GVHD predictors from clinical data.

Conclusions:

  • Biomarkers are essential for risk stratification and guiding treatment decisions in HCT.
  • Novel biomarkers offer potential therapeutic targets for GVHD and GVT.
  • Continued research in biomarkers and omics will enhance HCT outcomes.